Adult Dosing

Bacterial conjunctivitis

IQuix

• Days 1 through 3: 1-2 drops in the affected eye(s) q30 min-2 hrs while awake and approximately 4 and 6 hrs after retiring
• Day 4 through 16 (through treatment completion): 1-2 drops in the affected eye(s) q1-4 hrs while awake

Quixin

• Days 1 and 2: 1-2 drops in the affected eye(s) q2 hrs while awake (MAX: 8 times/day)
• Days 3 to 7: 1-2 drops in the affected eye(s) q4 hrs while awake (MAX: 4 times/day)

Pediatric Dosing

Bacterial conjunctivitis

Quixin

• Child > 1 yrs
• Days 1 and 2: 1-2 drops in the affected eye(s) q2 hrs while awake (MAX: 8 times/day)
• Days 3 to 7: 1-2 drops in the affected eye(s) q4 hrs while awake (MAX: 4 times/day)

IQuix

• Child > 6 yrs
• Days 1 through 3: 1-2 drops in the affected eye(s) q30 min-2 hrs while awake and approximately 4 and 6 hrs after retiring
• Day 4 through 16 (through treatment completion): 1-2 drops in the affected eye(s) q1-4 hrs while awake

[Outline]

• Adult Dosing
• Pediatric Dosing

• Indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria:

Gram-positive bacteria

• Corynebacterium species
• Staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus pneumoniae
• Viridans group streptococci

Gram-negative bacteria

• Pseudomonas aeruginosa
• Serratia marcescens
• Note: Efficacy for Corynebacterium species, Viridans group streptococci, and Serratia marcescens was studied in fewer than 10 infections

• Hx. of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustment

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustment

See Supplemental Patient Information

• Ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye
• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, even following a single dose
• Prolonged use may result in overgrowth of nonsusceptible organisms
• Discontinue use immediately at the first sign of rash or allergic reaction
• Avoid contaminating the applicator tip with material from the eye, fingers or other source
• While receiving treatment, patients should wear sunglasses and avoid exposure to bright light

Supplemental Patient Information

• Advise patients not to wear contact lenses if they have signs and symptoms of corneal ulcer
• Avoid contaminating the applicator tip with material from the eye, fingers or other source
• Advise patient to discontinue medication immediately and contact physican at the first sign of a rash or allergic reaction
• While receiving treatment, patients should wear sunglasses and avoid exposure to bright light

Iquix, Quixin interacts with :

	A-methapred
	Antacids
	Aristocort
	Azmacort
	Bactrim
	Budesonide
	Calcium Polycarbophil
	Carafate
	Cortisone
	Cortone
	Cutivate
	Decadron
	Depo-Medrol
	Dexamethasone
	Didanosine
	Entocort
	Entocort EC
	FiberCon
	Flo-Pred
	Flonase
	Flovent
	Flovent Diskus
	Flovent HFA
	Fluticasone
	Iron Products
	Kenalog
	Kenalog-10
	Kenalog-40
	Maxidex
	Medrol
	Methylprednisolone
	Millipred
	Nasacort allergy 24 Hour
	Nasacort AQ
	Omnipred
	Orapred
	Orapred ODT
	Orasone
	Ozudrex
	Pred forte
	Pred mild
	Prednisolone
	Prednisone
	Prelone
	Procainamide
	Pronestyl
	Pulmicort flexhaler
	Pulmicort respules
	Pulmicort turbuhaler
	Rayos
	Rhinocort
	Septra
	Solu-Medrol
	Sterapred
	Sterapred DS
	Sucralfate
	Triacet
	Triamcinolone
	Triderm
	Triesence
	Uceris
	Veramyst
	Veripred 20
	Videx
	Videx EC
	Zinc

Pregnancy Category:C

Breastfeeding: Safety unknown; however minimal systemic absorption. Maternal use of levofloxacin opthalmic presents negligible risk for the nursing infant. This information based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 December 2010).

• CNS: Headache
• GI: Taste disturbance, diarrhea, dyspepsia, nausea
• EENT: Decreased/blurred vision, instillation site irritation/discomfort, ocular infection, photophobia, ocular pain/discomfort, throat irritation
• MISC: Fever, infection, superinfection

• Anti-infective; inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination
• Minimal systemic absorption ; CYP450: unknown
• Renally excreted: Urine primarily (87% unchanged)
• Half-life: 6-8 hrs

US Trade Name(s)

• Iquix
• Quixin

US Availability

levofloxacin (generic)

• OPTH SOLN: 0.5 % (5 mL)

Iquix

• OPTH SOLN: 1.5% (5 mL)

Quixin

• OPTH SOLN: 0.5% (5 mL)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Oftaquix

UK Availability

Oftaquix

• OPTH SOLN: 0.5% (5 mL)

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Antibiotics

Quinolones

Infectious Disease

Antibiotics

Quinolones

Antimicrobials

Ophthalmic Anti-infectives

Infectious Disease

Ophthalmic Anti-infectives

Ophthalmic

Ophthalmic Anti-infectives